Report of Foreign Issuer (6-k)
March 19 2020 - 1:06PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of March, 2020
Commission
File Number: 001-37353
BIONDVAX
PHARMACEUTICALS LTD.
(Translation
of registrant’s name into English)
Jerusalem
BioPark, 2nd Floor
Hadassah
Ein Kerem Campus
Jeusalem,
Israel
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
____
On
March 19, 2020, BiondVax Pharmaceuticals Ltd. issued a press release providing comments from the Company’s CEO on the impact
of the COVID-19 Pandemic on the Company’s ongoing phase 3 clinical trial.
Exhibit
Index
Exhibits
99.1 of this Report on Form 6-K are hereby incorporated by reference into the Company's Registration Statement on Form F-3 (Registration
No. 333-201283).
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
BiondVax
Pharmaceuticals Ltd.
|
|
|
|
Date:
March 19, 2020
|
By:
|
/s/
Ron Babecoff
|
|
|
Ron
Babecoff
|
|
|
Chief
Executive Officer
|
2
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Mar 2024 to Apr 2024
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Apr 2023 to Apr 2024